Quick Facts: Ossofortin D Uses

• Supports management of Vitamin D insufficiency and deficiency.
• Assists in promoting bone health and calcium absorption.
• Used in regimens to help prevent osteomalacia and rickets.

---

Ossofortin D: Therapeutic Indications

Ossofortin D is intended for use in individuals who require supplementation of cholecalciferol (Vitamin D3). The main use of this supplement is to address and prevent Vitamin D insufficiency and deficiency, a common global health concern. Maintaining adequate Vitamin D levels is essential for promoting and maintaining skeletal health.

Vitamin D facilitates the body's absorption of calcium from the digestive tract, a mechanism that is necessary for proper bone mineralization. Through this action, Ossofortin D supports regimens aimed at maintaining healthy bones and managing conditions related to inadequate Vitamin D, such as osteomalacia in adults and rickets in children.

The inclusion of cholecalciferol also supports normal physiological functions, including neuromuscular and immune system processes.

Ossofortin D is intended for use primarily by adults and older adults who require supplementation. The official regulatory label strictly defines which populations are excluded or require restricted use based on pre-existing conditions and physiological status.

---

Contraindications (Must Not Use)

Use is absolutely prohibited for patients with elevated mineral levels, including Hypercalcaemia (high blood calcium) and Hypervitaminosis D (Vitamin D overdose). The medicine is also strictly contraindicated in cases of Severe Renal Insufficiency (kidney failure), Hypercalciuria (high calcium in urine), and specific conditions such as decalcifying tumors or known hypersensitivity to the components.

---

Conditional Use and Restrictions

Age-Group Eligibility: The product is generally not intended for use in children and adolescents for general supplementation.

Organ Function: Patients with non-severe renal impairment require caution and continuous laboratory monitoring due to altered mineral regulation. Caution is also necessary for patients with a history of renal calculi.

Pregnancy and Lactation: Use during pregnancy is highly restricted and conditional on a clear benefit-risk assessment. It is frequently contraindicated for breastfeeding mothers due to the potential for infant exposure to the potent Vitamin D Analog component.

Interactions with other medicines and products

Ossofortin D (containing calcium and cholecalciferol) has documented interactions with various medicinal products and substance categories, primarily affecting absorption or increasing the risk of high calcium levels in the body.

Interacting Product Categories and Agents

• Medicines affecting blood calcium: Thiazide diuretics may reduce the amount of calcium eliminated by the kidneys, increasing the risk of hypercalcaemia (high blood calcium) when taken with Ossofortin D. Close monitoring of serum and urinary calcium is officially required when these are used together.
• Cardiac medicines: Cardiac glycosides, such as digoxin, may have their effects accentuated if hypercalcaemia occurs, raising the risk of cardiac arrhythmias. ECG monitoring and calcium concentration checks are mandated for this combination.
• Agents with reduced absorption: The calcium component of Ossofortin D can significantly reduce the absorption of several medicines due to chelation. These include quinolone and tetracycline antibiotics, levothyroxine preparations, iron salts, zinc salts, strontium ranelate, and bisphosphonates.
• Other interacting agents: Corticosteroids may decrease calcium absorption, while high doses of absorbable alkali agents increase the risk of milk-alkali syndrome when combined with high calcium intake.

Required Separation of Administration

To minimize interference with the absorption of other medicines, official regulatory documents require specific timing constraints. Quinolone antibiotics should be taken at least two hours before or six hours after Ossofortin D. Levothyroxine and iron/zinc/strontium ranelate preparations typically require a separation of two to four hours from the intake of the calcium-containing supplement. Simultaneous use with estramustine is to be avoided due to significant reduction in the absorption of estramustine.

How Ossofortin D Works: Mechanism of Action

Hormonal Conversion and Nuclear Receptor Signaling

Ossofortin D (cholecalciferol) undergoes a required two-step hydroxylation process, occurring sequentially in the liver and the kidneys, to become its biologically active hormonal form, Calcitriol (1,25-dihydroxycholecalciferol). Calcitriol functions as an agonist for the Vitamin D Receptor (VDR), an intracellular receptor. The VDR-ligand complex modulates gene transcription, leading to the synthesis of proteins involved in mineral transfer and regulation.

---

️ Systemic Calcium and Phosphate Homeostasis

The VDR agonism primarily influences the pathways that govern systemic mineral homeostasis. This involves enhancing the absorption of calcium and phosphate across the small intestine and modulating renal reabsorption. The mechanism also participates in a regulatory feedback loop by suppressing the secretion of Parathyroid Hormone (PTH). This coordinated modulation influences the circulating concentrations of calcium and phosphate.

---

Skeletal Mineralization

By influencing the bioavailability of sufficient calcium and phosphate, the mechanism provides the necessary substrate for skeletal mineralization. This enables osteoblasts (bone-forming cells) to facilitate mineralization of the bone matrix by depositing hydroxyapatite, which is the fundamental process for the development and maturation of the mineralized skeletal tissue.

How Ossofortin D Is Used

Ossofortin D, a combination product containing Calcium Carbonate and Dihydrotachysterol, is administered according to a strict, standardized regimen designed to manage mineral metabolism. The course of treatment is organized around specific parameters regarding administration route, dosage, and monitoring requirements.

---

Official Administration Guidelines

Instruction	Detail
Route of Administration	The medicine is prescribed exclusively for oral use, available in forms such as tablets, capsules, or an oral solution.
Dosing Schedule	The standard adult regimen requires once-daily dosing. The Dihydrotachysterol component typically starts at 0.8 mg to 2.4 mg daily for a short initial period, followed by a lower, continuous maintenance dose often in the 0.2 mg to 1.0 mg range.
Timing in Relation to Meals	While the Dihydrotachysterol component may be taken without regard to food, the Calcium Carbonate component, following general guidance for high-dose mineral salts, is often directed to be taken with or immediately after meals to support optimal intake.
Dose Adjustment Interval	Changes to the daily dosage must be managed over a period of 4 to 8 weeks to allow for the stabilization of serum calcium levels, reflecting the drug's extended duration of action.
Concurrent Requirements	The regimen is conditional upon the simultaneous intake of adequate elemental calcium supplementation and is guided by the results of frequent laboratory monitoring of calcium in the blood.
Population-Specific Use	Separate, lower, weight- or age-based pediatric dosing schedules are available. For older adults, specific numerical adjustments are not typically specified.

---

These instructions outline a continuous, once-daily administration protocol that is inseparable from the requirement for concurrent calcium intake and regular clinical laboratory checks. The procedural steps are structured to ensure that any adjustments to the oral dose are implemented slowly and deliberately over a multi-week period.

Research evidence / Overview of studies for Ossofortin D

---

Evidence for Use in Correcting Vitamin D Status

Research has primarily examined the use of the medicine’s components through Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were studied in individuals with established low Vitamin D blood levels, known as deficiency or insufficiency. Researchers carefully monitored the status of key blood concentrations, specifically measuring 25-hydroxyvitamin D [25(OH)D] status and tracking measurements of serum calcium and phosphate concentrations. Findings indicate that research contributes to understanding symptom patterns associated with low Vitamin D status, focusing on how concentrations evolved during the measured time intervals. However, certainty remains low regarding a universal optimal target level for all individuals, as the specific concentration goal was observed in some studies but varied across research protocols.

Evidence for Use in Osteoporosis and Fracture Prevention

This area of research utilized long-term systematic reviews and meta-analyses that synthesized data from numerous large-scale clinical trials. These studies primarily explored the potential for the medicine's components to be applied in contexts assessing fracture incidence (including total and hip fractures) and monitored measurements of Bone Mineral Density (BMD) in older populations. Evidence from systematic reviews described the study designs that included the two components and the patterns observed in the measured outcomes. There is limited information for long-term outcomes that extend beyond five years for all specific combination regimens, and evidence quality varies across studies, with some trials reporting mixed findings regarding BMD change.

Research on Correcting Hypocalcaemia (Low Blood Calcium)

Research has explored the medicine’s role in low blood calcium, known as hypocalcaemia, mainly through Randomized Controlled Trials (RCTs) and comparative studies. These trials were studied for research contexts involving fluctuating or unstable symptoms related to systemic or functional imbalance. The key outcomes monitored were the monitoring of serum concentrations consistent with systemic balance, and the tracking of related hormone levels. The primary limitation here is that comparative evidence is lacking for the specific fixed-dose combination product, with much of the available evidence focusing on the synthetic Vitamin D analog component alone.

Studies in Specific Populations and Contexts

Research has specifically examined the use of the medicine's components in older adults, where the most comprehensive body of long-term data exists, as well as in children and adolescents for contexts like nutritional rickets. There is also limited research that was studied for an adjunct role in Polycystic Ovary Syndrome (PCOS) in a very specific group of overweight women. However, the results apply only to the populations studied, and data for certain groups remain insufficient.

Key Studies & References

1. Review of Synthetic Vitamin D Analogs in Hypocalcemia Management
2. Efficacy Study of Vitamin D in Polycystic Ovary Syndrome (PCOS) Adjunct Therapy

Common questions about Ossofortin D (FAQ)

---

Q: Is Ossofortin D a vitamin or a prescription medication?

Official sources classify Ossofortin D as a prescription-only medicine and an Antihypocalcemic Agent. While it contains a potent synthetic Vitamin D Analog, its regulatory class and potency mean it requires a healthcare provider's prescription for use.

Q: Is Ossofortin D used for bone health in general, or only specific conditions?

Official product information states that the medicine is indicated for managing specific conditions of mineral imbalance, such as those related to hypoparathyroidism. The drug's action on mineral balance is recognized as contributing to the maintenance of bone strength.

Q: How quickly does Ossofortin D usually start working?

Studies on the drug's components indicate that the potent synthetic component begins its pharmacological action relatively promptly after administration. However, because the goal is to reach a stable, regulated mineral balance, regulatory documents specify that dose adjustments are typically managed carefully over a period of several weeks.

Q: Is it normal to feel tired or headachy when starting Ossofortin D?

These specific symptoms are not listed among the most commonly reported side effects in the official safety information. However, an uncommon adverse reaction known as Hypercalcemia (high blood calcium) can occur. Regulatory documents note that Hypercalcemia may lead to non-specific symptoms such as fatigue or a general feeling of malaise.

Q: Is it safe to take Ossofortin D with daily multivitamins?

Official documents state that the medicine is strictly contraindicated (must not be used) in patients with Hypervitaminosis D (Vitamin D overdose). Official warnings note that the co-administration of products containing Vitamin D may increase the risk of this condition, which is a contraindication.

Q: Can I take Ossofortin D if I am also taking blood pressure medicine?

Official regulatory information identifies a potential interaction with a specific class of blood pressure medicines known as Thiazide diuretics. This combination can increase the risk of Hypercalcemia (high blood calcium). Regulatory guidance emphasizes the importance of close clinical monitoring of mineral levels when these medicines are used together.

Q: Is Ossofortin D generally used for men and women equally?

The official indications for use apply equally to both male and female patients. The conditions that Ossofortin D is prescribed for are treated the same way, provided the patient meets the general eligibility criteria outlined in the regulatory documents.

Q: What is the expected duration of treatment with Ossofortin D?

Official regulatory documents describe the use of this medicine for conditions requiring chronic support and management. Therefore, treatment with Ossofortin D is typically classified as a continuous, long-term maintenance therapy rather than a short-term course.

Q: Can Ossofortin D be used by people with lactose intolerance?

Whether the product is suitable for people with lactose intolerance depends on the inactive ingredients (excipients) used in the formulation. The complete list of excipients for the tablets, capsules, or oral solution is documented within the official product information.

Q: Are there different strengths or forms of Ossofortin D available?

Official prescribing information lists the various available formats of the medicine, which may include tablets, capsules, and an oral solution. Furthermore, regulatory documents specify the exact numerical strengths in which the commercial product is supplied.

Q: Is Ossofortin D described as having a risk of dependency?

No. Official regulatory documents specifically address drug abuse and dependence and indicate that Ossofortin D has no known potential for either abuse or physical dependence.

Q: Why is Ossofortin D sometimes recommended for people who have limited sun exposure?

The medicine contains a potent synthetic Vitamin D Analog. The synthetic analog is designed to help maintain mineral balance through a mechanism that is independent of the body's sun-activated Vitamin D pathway.

Q: Does Ossofortin D require any special handling or preparation before use?

Yes. Regulatory information outlines specific handling and storage requirements, such as keeping the medicine protected from both light and moisture in its original container. If an oral solution is prescribed, the official usage guidelines will contain instructions for any necessary preparation prior to administration.

Q: What happens if you forget to take Ossofortin D for a day?

Official administration guidelines include a procedure for missed doses. These instructions typically specify how to proceed and warn against taking double doses.

Q: What happens when a person stops taking Ossofortin D?

Regulatory documents state that any decision to stop or change treatment requires management and supervision by a healthcare professional. This is often necessary because the active component can have a prolonged duration of effect, or symptoms may return.

Q: Does Ossofortin D contain any common allergens like soy or gluten?

Official product information lists the complete formulation, including the inactive ingredients (excipients). This list would specify the presence of common allergens such as soy or gluten, allowing patients to check if these components are included in their prescribed form of the medicine.

Q: Can Ossofortin D affect mood or mental clarity?

Official safety warnings note that the primary risk associated with this medicine is Hypercalcemia (high blood calcium). If this mineral imbalance occurs, symptoms associated with it may include altered mental clarity, lethargy, or confusion.

Q: Do regulatory agencies list any black box warnings for Ossofortin D?

The presence or absence of a Black Box Warning, which is the most severe level of warning required by US regulatory agencies, is explicitly indicated or ruled out at the beginning of the official prescribing information.

Q: Why is Ossofortin D not available over-the-counter?

The medicine is classified as prescription-only due to the potent nature of its active components and the associated safety profile. Official warnings state that the narrow therapeutic window and significant risk of Hypercalcemia require mandatory, frequent clinical and laboratory monitoring by a healthcare professional.

How to Store and Dispose of Ossofortin D

Storage and disposal must strictly follow regulatory documentation to maintain product stability and safety. These requirements are not clinical advice.

Storage Requirements

Ossofortin D must be stored at a temperature below 25°C (77°F). It is required to be stored in conditions that provide protection from both light and moisture, which helps maintain the stability of the active components. To ensure this protection, the medicine must be kept in its original container.

Child Safety and Disposal

As a mandatory safety measure, the product must be stored out of the sight and reach of children.

When disposing of unused or expired Ossofortin D, the product must not be discarded via wastewater or household waste. Disposal must be performed in accordance with local regulatory requirements for pharmaceutical waste.